Quarterly
Annual
| Unit: USD | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2019-03-31 | 2018-03-31 | 2011-04-02 | 2010-10-02 |
|---|---|---|---|---|---|---|---|---|
cash flows from operating activities: | ||||||||
net earnings | 15,835,000 | 13,394,000 | 12,019,000 | 10,763,000 | 8,911,000 | 8,101,000 | 8,000,000 | 27,351,000 |
adjustments to reconcile net earnings to net cash from operating activities: | ||||||||
depreciation | 4,580,000 | 4,599,000 | 4,216,000 | 4,365,000 | ||||
deferred income taxes | -345,000 | 10,000 | 208,000 | 174,000 | 149,000 | -415,000 | ||
amortization (accretion) of marketable security premiums / discounts | ||||||||
changes in operating assets and liabilities: | ||||||||
accounts receivable | 11,378,000 | -360,000 | 3,092,000 | 6,326,000 | 5,927,000 | 5,858,000 | 1,807,000 | |
other receivables | 2,626,000 | 645,000 | -239,000 | 487,000 | -267,000 | -2,729,000 | 1,761,000 | |
inventories | -13,262,000 | -24,432,000 | -12,051,000 | -8,883,000 | -11,100,000 | -12,845,000 | ||
prepaid expenses and other assets | -250,000 | 1,033,000 | 1,829,000 | 572,000 | 983,000 | 4,052,000 | 1,723,000 | 2,155,000 |
accounts payable and accrued liabilities | -3,414,000 | -4,845,000 | 4,296,000 | -1,204,000 | -2,770,000 | -501,000 | 455,000 | 9,067,000 |
income taxes payable | 3,797,000 | 1,536,000 | 2,213,000 | 2,295,000 | 2,930,000 | 2,761,000 | ||
postretirement health care benefits | -152,000 | -201,000 | -209,000 | -347,000 | -150,000 | -233,000 | ||
deferred compensation and other liabilities | -34,000 | -46,000 | 99,000 | 50,000 | 924,000 | 584,000 | 456,000 | 838,000 |
net cash from operating activities | 21,401,000 | -7,482,000 | 16,807,000 | 15,337,000 | 10,556,000 | 9,667,000 | 3,724,000 | |
cash flows from investing activities: | ||||||||
capital expenditures | -4,494,000 | -5,049,000 | -5,948,000 | -3,787,000 | -4,683,000 | -7,722,000 | ||
free cash flows | 16,907,000 | -12,531,000 | 10,859,000 | 11,550,000 | 5,873,000 | 1,945,000 | ||
purchases of trading securities | -1,296,000 | -1,010,000 | -737,000 | -1,835,000 | -2,360,000 | -3,258,000 | ||
sales of trading securities | 430,000 | 528,000 | 205,000 | 582,000 | 362,000 | 239,000 | ||
purchase of available for sale securities | -27,297,000 | -14,848,000 | -25,148,000 | -30,031,000 | -20,919,000 | -34,061,000 | ||
sale and maturity of available for sale securities | 12,655,000 | 25,874,000 | 8,524,000 | 8,543,000 | 5,379,000 | 11,670,000 | 55,000 | 2,005,000 |
net cash from investing activities | -20,002,000 | 5,495,000 | -23,104,000 | -26,528,000 | -22,221,000 | -33,132,000 | ||
cash flows from financing activities: | ||||||||
shares purchased and retired | -1,604,000 | -1,152,000 | -7,423,000 | -10,519,000 | -12,498,000 | |||
dividends paid in cash | -12,491,000 | -12,291,000 | -12,075,000 | -11,874,000 | -11,530,000 | -11,282,000 | ||
proceeds from bank loans | 1,039,000 | 1,110,000 | 1,178,000 | 1,070,000 | 941,000 | 641,000 | ||
repayment of bank loans | -1,055,000 | -1,115,000 | -1,016,000 | -896,000 | -544,000 | -661,000 | ||
net cash from financing activities | -12,507,000 | -13,900,000 | -13,065,000 | -19,123,000 | -21,652,000 | -23,800,000 | ||
effect of exchange rate changes on cash | 71,000 | 613,000 | 313,000 | -252,000 | 80,000 | 829,000 | ||
increase in cash and cash equivalents | -19,049,000 | -30,566,000 | ||||||
cash, cash equivalents and restricted cash at beginning of year | 76,290,000 | 53,635,000 | 106,226,000 | 167,256,000 | 111,287,000 | 96,720,000 | ||
cash, cash equivalents and restricted cash at end of quarter | 65,253,000 | 38,361,000 | 87,177,000 | 136,690,000 | 78,050,000 | 50,284,000 | ||
| ||||||||
supplemental cash flow information: | ||||||||
income taxes paid | 1,302,000 | 4,111,000 | ||||||
interest paid | 66,000 | 58,000 | 2,000 | 2,000 | 31,000 | 24,000 | 25,000 | 88,000 |
stock dividend issued | 66,243,000 | 86,433,000 | 70,242,000 | 64,667,000 | 70,557,000 | 60,538,000 | 47,054,000 | 0 |
amortization of marketable security premiums | 642,000 | 1,185,000 | 1,334,000 | 739,000 | 353,000 | 456,000 | ||
decrease in cash and cash equivalents | -11,037,000 | -15,274,000 | -33,237,000 | -46,436,000 | ||||
cash, cash equivalents and restricted cash at end of year | ||||||||
income taxes paid/(received) | 565,000 | 2,303,000 | 1,571,000 | 1,233,000 | -20,000 | -206,000 | ||
repayment of premiums on split dollar life insurance policies | ||||||||
impairment of majority-owned foreign subsidiaries | ||||||||
depreciation and amortization | 4,666,000 | 4,578,000 | 4,605,000 | 4,618,000 | ||||
impairment of majority-owned spanish subsidiaries | ||||||||
change in restricted cash | ||||||||
cash and cash equivalents at beginning of year | 115,976,000 | |||||||
cash and cash equivalents at end of year | ||||||||
restricted cash | ||||||||
cash and cash equivalents at end of quarter | 84,908,000 | |||||||
net income on step acquisition | ||||||||
net cash acquired in step acquisition | ||||||||
postretirement health care and life insurance benefits | 530,000 | 348,000 | ||||||
impairment of equity method investment | ||||||||
income from equity method investment | ||||||||
loss on step acquisition | ||||||||
income taxes payable and deferred | ||||||||
net sales (purchases) of trading securities | ||||||||
other | 241,000 | 319,000 | ||||||
net purchases of trading securities | ||||||||
(gain) income from equity method investment | ||||||||
increase(decrease) in cash and cash equivalents | ||||||||
purchase of available-for-sale securities | ||||||||
sale and maturity of available-for-sale securities | ||||||||
amortization of marketable securities | 169,000 | 135,000 | ||||||
cash and cash equivalents-beginning of year | 0 | |||||||
cash and cash equivalents end of quarter | -1,144,000 | |||||||
shares repurchased and retired |
The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.